Thrombosis Research
Volume 124, Issue 6 , Pages 672-677 , December 2009

Short term effect of recombinant tissue plasminogen activator in patients with hemodynamically stable acute pulmonary embolism: Results of a meta-analysis involving 464 patients

  • B. Tardy

      Affiliations

    • Intensive Care Unit, CHU, Saint Etienne, 42055, France
    • Inserm CIE3, CHU Saint Etienne, 42055, France
    • Corresponding Author InformationCorresponding author. Intensive Care Unit, CHRU, Saint Etienne, 42055, France. Tel.: +33 4 77 12 07 97.
    • ,
  • C. Venet

      Affiliations

    • Intensive Care Unit, CHU, Saint Etienne, 42055, France
    • ,
  • F. Zeni

      Affiliations

    • Intensive Care Unit, CHU, Saint Etienne, 42055, France
    • ,
  • M. Coudrot

      Affiliations

    • Intensive Care Unit, CHU, Saint Etienne, 42055, France
    • ,
  • S. Guyomarc'h

      Affiliations

    • Intensive Care Unit, CHU, Saint Etienne, 42055, France
    • ,
  • P. Mismetti

      Affiliations

    • Groupe de Recherche sur la Thrombose EA 3065, CHU Sait Etienne, France

Received 20 March 2009 ,Revised 12 May 2009 ,Accepted 12 May 2009.

References 

  1. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians. Evidenced-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:454S–545S
  2. Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galiè N, Pruszczyk P, et al. Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J. 2008;29:2276–2315
  3. Agnelli G, Becattini C, Kirschstein T. Thrombolysis vs heparin in the treatment of pulmonary embolism: a clinical outcome-based meta-analysis. Arch Intern Med. 2002;162:2537–2541
  4. Thabut G, Thabut D, Myers RP, Bernard-Chabert B, Marrash-Chahla R, Mal H, et al. Thrombolytic therapy of pulmonary embolism: a meta-analysis. J Am Coll Cardiol. 2002;40:1660–1667
  5. Wan S, Quinlan DJ, Agnelli G, Eikelboom JW. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism. Circulation. 2004;110:744–749
  6. Ribeiro A, Lindmarker P, Juhlin-Dannfelt A, Johnsson H, Jorfeldt L. Echocardiography Doppler in pulmonary embolism: right ventricular dysfunction as a predictor of mortality rate. Am Heart J. 1997;134:479–487
  7. Grifoni S, Olivotto I, Cecchini P, Pieralli F, Camaiti A, Santoro G, et al. Short term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfuction. Circulation. 2000;101:2817–2822
  8. Konstantinides S, Geibel A, Olschewski M, Heinrich F, Grosser K, Rauber K, et al. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: results of a multicenter registry. Circulation. 1997;96:882–888
  9. Urokinase Pulmonary Embolism Trial Study Group . Urokinase pulmonary embolism trial: phase 1 results. JAMA. 1970;214:2163–2172
  10. Sharma GV, Burleson VA, Sasahara AA. Effects of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism. N Engl J Med. 1980;303:842–845
  11. Sasahara AA, Sharma GV, Parisi AF, Barsamian EM, McIntyre KM, Tow DE, et al. Pulmonary embolism, pulmonary microcirculation, and thrombolytic therapy. Angiology. 1982;33:368–374
  12. Giuntini C, Marini C, Di Rocco G, Palla R, Giacomelli V, Rindi M. A controlled clinical trial on the effects of heparin infusion and two regimens of urokinase in acute pulmonary embolism. G Ital Cardiol. 1984;14(suppl 1):26–29
  13. Palla A, Pazzagli M, Manganelli D, De Nitto P, Marini C, Rossi G, et al. Resolution of pulmonary embolism: effect of therapy and putative age of emboli. Respiration. 1997;64:50–53
  14. Sharma GV, Folland ED, McIntyre KM, Sasahara AA. Long term benefit of thrombolytic therapy in patients with pulmonary embolism. Vasc Med. 2000;5:91–95
  15. The Urokinase Pulmonary Embolism Trial . A national cooperative study. Circulation. 1973;47(suppl 2):1–108
  16. Tibbutt DA, Davies JA, Anderson JA, Fletcher EWL, Hamill J, Holt JM, et al. Comparison by controlled clinical trial of streptokinase and heparin in treatment of life threatening pulmonary embolism. BMJ. 1974;1:343–347
  17. Ly B, Arnesen H, Eie H, Hol R. A controlled clinical trial of streptokinase and heparin in the treatment of major pulmonary embolism. Acta Med Scand. 1978;203:465–470
  18. Dotter CT, Seaman AJ, Rösch J, Porter JM. Streptokinase and heparin in the treatment of pulmonary embolism: a randomized comparison. Vasc Surg. 1979;13:42–52
  19. Marini C, Di Rocco G, Rossi G, Rindi M, Palla R, Giuntini C. Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: a randomized clinical trial. Respiration. 1988;54:162–173
  20. Jerjes-Sanchez C, Ramirez-Riveroa A, de Lourdes Garcia M, Arriaga-Nava R, Valencia S, Rosado-Buzzo A, et al. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial. J Thromb Thrombolysis. 1995;2:227–229
  21. Cheng X, He J, Gao M, Chen G, Li S, Zhang Z, et al. Multicenter clinical trial on the efficacy of thrombolytic therapy with urokinase and/or anticoagulant with low molecular weight heparin in acute pulmonary embolism. Zhonghua Nei Ke ZA Zhi. 2002;41:6–10
  22. Levine M, Hirsh J, Weitz J, Cruickshank M, Neemeh J, Turpie AG, et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with pulmonary embolism. Chest. 1990;98:1473–1479
  23. PIOPED investigators . Tissue plasminogen activator for the treatment of acute pulmonary embolism: a collaborative study. Chest. 1990;97:528–533
  24. Dalla-Volta S, Palla A, Santolicandro A, Giuntini C, Pengo V, Visioli O, et al. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen Activator Italian Multicenter study 2. JACC. 1992;20:520–526
  25. Goldhaber SZ, Haire WD, Feldstein ML, Miller M, Toltzis R, Smith JL, et al. Alteplase versus heparin in acute pulmonary embolism: randomized trial assessing right ventricular function and pulmonary perfusion. Lancet. 1993;341:507–511
  26. Konstantinides S, GeiBel A, Heusel G, Heinrich F, Kasper W. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med. 2002;347:1143–1150
  27. The Matisse Investigators . Subcutaneous Fondaparinux versus unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003;349:1695–1702
  28. Hamel E, Pacouret G, Vincentelli D, Forissier JF, Peycher P, Pottier JM, et al. Thrombolysis and heparin therapy in massive pulmonary embolism with right ventricular dilatation: results from a 128-patient monocenter registry. Chest. 2001;120:120–125
  29. Pruszcyk P, Bochowicz A, Kostrubiec M, Torbicki A, Szulc M, Gurba H, et al. Myoglobin stratifies short term risk in acute major pulmonary embolism. Clin Chim Acta. 2003;338:53–56
  30. Kucher N, Wallmann D, Carone A, Windecker S, Meier B, Hess OM. Incremental prognostic value of troponin I and echography in patients with acute pulmonary embolism. Eur Heart J. 2003;24:1651–1656
  31. Konstantinides S, Geibel A, Olschewski M, Kasper W, Hruska N, Jac S, et al. Importance of cardiac troponins I and T in risk stratification patients with acute pulmonary embolism. Circulation. 2002;106:1263–1268
  32. Ten Wolde M, Tulevski II, Mulder JWM, Söhne M, Boomsma F, Mulder BJM, et al. Brain natriuretic peptide as a predictor of adverse outcome in patients with pulmonary embolism. Circulation. 2003;107:2082–2084

PII: S0049-3848(09)00224-2

doi: 10.1016/j.thromres.2009.05.009

Thrombosis Research
Volume 124, Issue 6 , Pages 672-677 , December 2009

Article Tools

* Image Usage & Resolution